KemPharm market cap is $42 m, and annual revenue was $12.84 m in FY 2019

KemPharm Net income (Q2, 2020)859 K

KemPharm EBIT (Q2, 2020)2.6 M

KemPharm Cash, 30-Jun-20206.4 M

KemPharm EV103.7 M

USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|

## Revenue | 12.8m | ||||

## Cost of goods sold | 10.0m | ||||

## Gross profit | 2.8m | ||||

| 22% | ||||

## R&D expense | 13.9m | 20.5m | 20.6m | 41.8m | 19.4m |

## General and administrative expense | 8.9m | 14.0m | 12.8m | 12.5m | 10.8m |

## Operating expense total | 22.8m | 34.5m | 33.4m | 54.3m | 23.2m |

## EBIT | (22.8m) | (37.5m) | (33.4m) | (55.9m) | (20.3m) |

| (158%) | ||||

## Interest expense | 31.8m | 21.0m | 10.1m | 689.0k | 4.2m |

## Interest income | 32.0k | 353.0k | 365.0k | 420.0k | 309.0k |

## Pre tax profit | (54.6m) | (16.5m) | (43.4m) | (56.6m) | (24.5m) |

## Income tax expense | 26.0k | (15.0k) | (43.0k) | (126.0k) | (22.0k) |

## Net Income | (54.7m) | (16.5m) | (43.4m) | (56.5m) | (24.5m) |

USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|

## Cash | 32.3m | 16.8m | 10.9m | 18.4m | 3.2m |

## Accounts Receivable | 2.0m | 140.0k | 1.7m | ||

## Prepaid Expenses | 1.7m | 2.1m | 1.6m | ||

## Inventories | 2.8m | 489.0k | |||

## Current Assets | 54.1m | 74.4m | 47.0m | 23.7m | 6.6m |

## PP&E | 403.0k | 2.0m | 2.0m | 1.8m | 1.5m |

## Total Assets | 55.7m | 84.9m | 52.5m | 26.7m | 10.5m |

## Accounts Payable | 4.9m | 6.4m | 2.2m | 3.7m | 1.1m |

## Short-term debt | 3.3m | 3.3m | 80.2m | ||

## Current Liabilities | 8.3m | 6.6m | 11.5m | 12.0m | 5.4m |

## Long-term debt | 92.7m | 81.4m | 77.3m | ||

## Total Debt | 96.1m | 84.8m | 157.5m | ||

## Total Liabilities | 103.6m | 110.0m | 93.3m | 85.0m | |

## Common Stock | 1.0k | 3.0k | 4.0k | ||

## Preferred Stock | |||||

## Additional Paid-in Capital | 94.7m | 102.6m | 107.2m | 154.6m | 171.3m |

## Retained Earnings | (104.8m) | (121.3m) | (164.7m) | (221.2m) | (245.7m) |

## Total Equity | (10.1m) | (18.7m) | (57.5m) | (66.6m) | (74.5m) |

## Debt to Equity Ratio | -1.7 x | -1.3 x | |||

## Debt to Assets Ratio | 1.8 x | 3.2 x | |||

## Financial Leverage | -5.5 x | -4.5 x | -0.9 x | -0.4 x | -0.1 x |

USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|

## Net Income | (54.7m) | (16.5m) | (43.4m) | (56.5m) | (24.5m) |

## Depreciation and Amortization | 84.0k | 175.0k | 336.0k | 324.0k | 304.0k |

## Accounts Receivable | (4.5m) | (1.7m) | |||

## Inventories | (1.2m) | (15.9m) | |||

## Accounts Payable | 1.3m | 1.1m | (801.0k) | (1.6m) | (3.8m) |

## Cash From Operating Activities | (20.3m) | (29.8m) | (33.1m) | (54.2m) | (23.7m) |

## Purchases of PP&E | (135.0k) | (643.0k) | (181.0k) | (21.0k) | (26.0k) |

## Cash From Investing Activities | (19.1m) | (46.9m) | 27.4m | 33.3m | 3.2m |

## Long-term Borrowings | (157.0k) | (193.0k) | (207.0k) | ||

## Cash From Financing Activities | 61.5m | 61.2m | (203.0k) | 28.0m | 4.9m |

## Net Change in Cash | (5.9m) | 7.1m | (15.6m) | ||

## Interest Paid | 3.0k | 3.3m | 5.7m | 5.6m | 5.4m |

USD | Q1, 2015 |
---|---|

## Financial Leverage | -0.3 x |